全文获取类型
收费全文 | 1492篇 |
免费 | 116篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 37篇 |
妇产科学 | 41篇 |
基础医学 | 150篇 |
口腔科学 | 13篇 |
临床医学 | 164篇 |
内科学 | 401篇 |
皮肤病学 | 8篇 |
神经病学 | 80篇 |
特种医学 | 51篇 |
外科学 | 161篇 |
综合类 | 45篇 |
预防医学 | 102篇 |
眼科学 | 207篇 |
药学 | 87篇 |
肿瘤学 | 58篇 |
出版年
2023年 | 8篇 |
2021年 | 14篇 |
2020年 | 9篇 |
2019年 | 18篇 |
2018年 | 14篇 |
2017年 | 19篇 |
2016年 | 23篇 |
2015年 | 20篇 |
2014年 | 36篇 |
2013年 | 53篇 |
2012年 | 74篇 |
2011年 | 72篇 |
2010年 | 38篇 |
2009年 | 28篇 |
2008年 | 78篇 |
2007年 | 79篇 |
2006年 | 80篇 |
2005年 | 65篇 |
2004年 | 67篇 |
2003年 | 62篇 |
2002年 | 55篇 |
2001年 | 48篇 |
2000年 | 56篇 |
1999年 | 48篇 |
1998年 | 12篇 |
1997年 | 11篇 |
1996年 | 19篇 |
1995年 | 12篇 |
1994年 | 19篇 |
1993年 | 11篇 |
1992年 | 43篇 |
1991年 | 46篇 |
1990年 | 35篇 |
1989年 | 28篇 |
1988年 | 46篇 |
1987年 | 30篇 |
1986年 | 17篇 |
1985年 | 24篇 |
1984年 | 19篇 |
1983年 | 14篇 |
1982年 | 12篇 |
1981年 | 12篇 |
1980年 | 8篇 |
1979年 | 11篇 |
1978年 | 10篇 |
1977年 | 11篇 |
1974年 | 13篇 |
1973年 | 11篇 |
1972年 | 10篇 |
1971年 | 8篇 |
排序方式: 共有1614条查询结果,搜索用时 31 毫秒
31.
32.
33.
34.
Background
The last decade has seen a number of methodological developments in meta-analysis of diagnostic test studies. However, it is unclear whether such developments have permeated the wider research community and on which applications they are being deployed. The objective was to assess the uptake and deployment of the main methodological developments in the meta-analysis of diagnostic tests, and identify the tests and target disorders most commonly evaluated by meta-analysis. 相似文献35.
The evaluation of gastrointestinal function in diabetic patients 总被引:2,自引:0,他引:2
Quigley EM 《World journal of gastroenterology : WJG》1999,5(4):13-282
Nowadays,anumberofoptionsareavailablefortheasesmentofgastricmotorfunction.Thus,aglobalevaluationofgastricmotorfunctionmaybeob... 相似文献
36.
37.
Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height 总被引:6,自引:0,他引:6
Quigley CA Crowe BJ Anglin DG Chipman JJ 《The Journal of clinical endocrinology and metabolism》2002,87(5):2033-2041
A cardinal clinical feature of Turner syndrome (TS) is linear growth failure resulting in extreme short stature: the median adult height of untreated women with TS is 143 cm, 20 cm (8 in.) below that of the general female population. In the largest multicenter, randomized, long-term, dose-response study conducted in the United States, 232 subjects with TS received either 0.27 or 0.36 mg/kg.wk of recombinant human GH with either low dose ethinyl E2 or oral placebo. The study was placebo-controlled for both GH and estrogen for the first 18 months and remained placebo-controlled for estrogen for its duration. The near-final height of the 99 subjects whose bone age was at least 14 yr was 148.7 +/- 6.1 cm after 5.5 +/- 1.8 yr of GH started at a mean age of 10.9 +/- 2.3 yr; this represents an average increase of 1.3 +/- 0.6 SD scores from baseline (TS standard). Height was greater than 152.4 cm (60 in.) in 29% of subjects compared with the expected 5% of untreated patients. Mean near-final heights of subjects who received the lower GH dose, with or without estrogen, were 145.1 +/- 5.4 and 149.9 +/- 6.0 cm, respectively; those who received the higher GH dose with or without estrogen achieved mean near-final heights of 149.1 +/- 6.0 and 150.4 +/- 6.0 cm, respectively. Factors that most impacted outcome were younger age, lower bone age/chronological age ratio, lower body weight, and greater height SD score at study entry. This study demonstrates significant GH-induced improvement in height SD score, with correction of height to within the normal channels for a significant number of patients, and provides evidence of a GH dose-response effect. These data also indicate that early administration of estrogen, even at relatively low doses, does not improve gain in near-final height in patients with TS. 相似文献
38.
C A Quigley K J Friedman A Johnson R G Lafreniere L M Silverman D B Lubahn T R Brown E M Wilson H F Willard F S French 《The Journal of clinical endocrinology and metabolism》1992,74(4):927-933
The molecular basis of androgen insensitivity was investigated in a family with the complete form of the syndrome. Polymerase chain reaction amplification and Southern blot analysis of genomic DNA revealed a deletion of the entire androgen receptor (AR) gene in affected individuals. The carrier status of female members of this family was examined using a HindIII restriction fragment length polymorphism associated with the AR gene. Obligate carriers were hemizygous for one of the two alleles at this locus, while heterozygosity for the polymorphic alleles, implying the presence of two copies of the AR gene, indicated noncarrier status. This conclusion was supported by gene dosage studies using comparative densitometric analysis of Southern blots hybridized simultaneously with an AR cDNA probe and a control cDNA probe from an unrelated gene. Finally, the pattern of inheritance of another X-linked DNA polymorphism allowed us to conclude that the original mutation had occurred in the germ line of the maternal great-grandfather of the index patient. Although rare, complete deletion of the AR gene is of particular importance in terms of correlation between molecular defect and phenotype, as it represents the quintessential form of complete androgen insensitivity, the null phenotype. 相似文献
39.
Dale Lupu Leo Quigley Nicholas Mehfoud Edward S. Salsberg 《Journal of pain and symptom management》2018,55(4):1216-1223
Context
The need for hospice and palliative care is growing rapidly as the population increases and ages and as both hospice and palliative care become more accepted. Hospice and palliative medicine (HPM) is a relatively new physician specialty, currently training 325 new fellows annually. Given the time needed to increase the supply of specialty-trained physicians, it is important to assess future needs to guide planning for future training capacity.Objectives
We modeled the need for and supply of specialist HPM physicians through the year 2040 to determine whether training capacity should continue growing.Methods
To create a benchmark for need, we used a population-based approach to look at the current geographic distribution of the HPM physician supply. To model future supply, we calculated the annual change in current supply by adding newly trained physicians and subtracting physicians leaving the labor force.Results
The current U.S. supply of HPM specialists is 13.35 per 100,000 adults 65 and older. This ratio varies greatly across the country. Using alternate assumptions for future supply and demand, we project that need in 2040 will range from 10,640 to almost 24,000 HPM specialist physicians. Supply will range from 8100 to 19,000.Conclusion
Current training capacity is insufficient to keep up with population growth and demand for services. HPM fellowships would need to grow from the current 325 graduates annually to between 500 and 600 per year by 2030 to assure sufficient physician workforce for hospice and palliative care services given current service provision patterns. 相似文献40.
J F Ropert M E Quigley S S Yen 《The Journal of clinical endocrinology and metabolism》1981,52(3):583-585
To test the postulate that endogenous opioid peptides may be involved in the neuroendocrine mechanisms controlling the frequency and amplitude of LH pulses, saline and an opioid receptor antagonist, naloxone, were infused sequentially, each for 6-h intervals, in six normal cycling women during the luteal phase of the menstrual cycle. During naloxone infusion (1.6 mg/h), there was a significant (P less than 0.01) increase in both the frequency and amplitude of LH pulses compared to those in saline controls. FSH pulses were not discernible in individual subjects; however, a significant increment in FSH levels occurred concomitantly with the increase in LH. These data strongly suggest that endogenous opiates, through an inhibition of hypothalamic LRF, participate in the endocrine events leading to the low frequency of episodic LH secretion characteristic of the luteal phase of the human menstrual cycle. 相似文献